Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for metastatic cancers, including colorectal, pancreatic, breast, lung, and melanoma. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets, such as the checkpoint protein PD-L1. The company has a collaboration agreement with NRG Oncology. Tocagen Inc. was founded in 2007 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-412-8400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$40,000.00
Profitability
Miscellaneous
Employees67
OptionableOptionable
Tocagen (NASDAQ:TOCA) Frequently Asked Questions
What is Tocagen's stock symbol?
Tocagen trades on the NASDAQ under the ticker symbol "TOCA."
How were Tocagen's earnings last quarter?
Tocagen Inc (NASDAQ:TOCA) announced its earnings results on Thursday, November, 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.22. The company had revenue of $18.01 million for the quarter, compared to analysts' expectations of $2.01 million. Tocagen had a negative net margin of 222.81% and a negative return on equity of 71.61%. View Tocagen's Earnings History.
When is Tocagen's next earnings date?
What price target have analysts set for TOCA?
6 equities research analysts have issued 12-month price objectives for Tocagen's stock. Their predictions range from $15.00 to $30.00. On average, they anticipate Tocagen's stock price to reach $22.3333 in the next year. This suggests a possible upside of 152.1% from the stock's current price. View Analyst Price Targets for Tocagen.
What is the consensus analysts' recommendation for Tocagen?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tocagen in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tocagen.
Has Tocagen been receiving favorable news coverage?
Media coverage about TOCA stock has been trending somewhat negative this week, according to InfoTrie. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tocagen earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.
Who are some of Tocagen's key competitors?
Some companies that are related to Tocagen include Urogen Pharma (URGN), Rocket Pharmaceuticals (RCKT), Intra-Cellular Therapies (ITCI), Dicerna Pharmaceuticals (DRNA), Eagle Pharmaceuticals (EGRX), Revance Therapeutics (RVNC), Omeros (OMER), CannTrust (CNTTF), Vectura Group (VEGPF), ANI Pharmaceuticals (ANIP), Ra Pharmaceuticals (RARX), Aurinia Pharmaceuticals (AUPH), Lexicon Pharmaceuticals (LXRX), ChemoCentryx (CCXI) and Viking Therapeutics (VKTX).
Who are Tocagen's key executives?
Tocagen's management team includes the folowing people:
- Mr. Martin J. Duvall, CEO & Director (Age 57)
- Mr. Thomas E. Darcy, Co-Founder & Director (Age 68)
- Mr. Mark G. Foletta CPA, Exec. VP & CFO (Age 58)
- Dr. Lori Anne Kunkel, Acting Chief Medical Officer (Age 61)
- Dr. Harry E. Gruber, Co-Founder, Pres of Science & Innovation and Director (Age 66)
When did Tocagen IPO?
(TOCA) raised $80 million in an IPO on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel acted as the underwriters for the IPO.
Who are Tocagen's major shareholders?
Tocagen's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Meeder Asset Management Inc. (0.05%). Company insiders that own Tocagen stock include Asha Das, Harry E Gruber, Mark G Foletta and Paul Schimmel. View Institutional Ownership Trends for Tocagen.
Which institutional investors are buying Tocagen stock?
TOCA stock was purchased by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc.. Company insiders that have bought Tocagen stock in the last two years include Asha Das, Harry E Gruber, Mark G Foletta and Paul Schimmel. View Insider Buying and Selling for Tocagen.
How do I buy shares of Tocagen?
Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tocagen's stock price today?
One share of TOCA stock can currently be purchased for approximately $8.86.
How big of a company is Tocagen?
Tocagen has a market capitalization of $176.78 million and generates $40,000.00 in revenue each year. The company earns $-38,920,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. Tocagen employs 67 workers across the globe.
What is Tocagen's official website?
How can I contact Tocagen?
Tocagen's mailing address is 4242 CAMPUS POINT COURT SUITE 500, SAN DIEGO CA, 92121. The company can be reached via phone at 858-412-8400 or via email at [email protected]
MarketBeat Community Rating for Tocagen (NASDAQ TOCA)
MarketBeat's community ratings are surveys of what our community members think about Tocagen and other stocks. Vote "Outperform" if you believe TOCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TOCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
